Curative Biotechnology, Inc. Announces Letter to Shareholders

Core Insights - Curative Biotechnology Inc. is implementing significant strategic changes to enhance its clinical program for metformin-based eye drops aimed at treating degenerative eye diseases, which includes establishing partnerships and revising its capital structure [1][2][3] Strategic Developments - The company is pursuing a manufacturing and/or full product development sublicense agreement for its metformin-based eye drops, with negotiations expected to conclude by year-end [3] - The focus will also expand to canine degenerative eye diseases, specifically Central Progressive Retinal Atrophy (CPRA) and Progressive Retinal Atrophy (PRA), leveraging preclinical data from human trials for regulatory approval [4][5][6] Capital Structure Changes - The company has withdrawn its S-1 registration statement and approved a revised reverse stock split ratio of 150-to-1, aimed at aligning its capital structure with the new strategic direction [7][17] - This restructuring is intended to de-risk operational execution, ensure a reliable supply chain, and provide non-dilutive funding through milestone payments [7] Market Potential - The veterinary ophthalmic drug market is estimated to be between $1.5 billion and $2.0 billion annually, with both CPRA and PRA representing significant unmet medical needs [6] Future Plans - Following the execution of the strategic sublicense agreement and the reverse stock split, the company plans to apply for uplisting to the OTCQB Venture Market [10]